Pay in 4 interest-free payments of $5.12 Learn more
Ships within 48 hours · Estimated delivery Aug 14 - Aug 19
Primary candidates for GLP-1 therapy include: Patients with type 2 diabetes and inadequate glycemic control despite metformin therapy Individuals with type 2 diabetes and established atherosclerotic cardiovascular disease Patients with type 2 diabetes and multiple cardiovascular risk factors (hypertension, dyslipidemia, obesity) Adults with obesity (BMI 30 kg/m) or overweight (BMI 27 kg/m) with weight-related comorbidities Patients with metabolic syndrome who have not achieved adequate risk factor control with lifestyle modification For patients with dyslipidemia, GLP-1 agents may be particularly valuable when combined with statin therapy in those who have not reached LDL-C goals or who have persistent hypertriglyceridemia despite statin treatment
As, la narrativa sobre obesidad evoluciona, alejndose del estigma y acercndose a una visin ms comprensiva y basada en la ciencia
The drug functions by obstructing the activities of estrogen, a hormone that accelerates the proliferation of breast cancer cells
Practitioners should utilize the following checklist during the initial assessment for any patient currently prescribed an incretin-based therapy: Medication Phase : Identify if the patient is in the initiation, escalation, or maintenance phase of treatment
US$ 28.09
US$ 23.13
US$ 23.32
US$ 29.10
US$ 28.42
US$ 25.58
US$ 28.01
US$ 25.09
US$ 22.49
US$ 25.12
US$ 24.83
US$ 28.98
US$ 28.36
US$ 21.69
US$ 29.39
